The National Institute for Health and Care Excellence

MHRA and NICE aligned pathway: how it's working in practice

Although the aligned pathway is central to our work, the benefits of improved collaboration between MHRA and NICE go beyond it. A recent example is aficamten, a new daily pill for people with ...
National Institute for Health and Care Excellence

Benefits of new Alzheimer’s treatment lecanemab are too small to justify the cost to the NHS

The benefits of the new Alzheimer’s drug lecanemab are too small to justify the costs, NICE said in draft guidance published today. Lecanemab (also called Leqembi and made by Eisai) is for slowing ...
National Institute for Health and Care Excellence

Weekly insulin jab could cut injections from 365 a year to just 52

Hundreds of thousands of people with type 2 diabetes could swap daily insulin injections for a once-a-week jab, following a NICE recommendation today (Thursday, 20 August). The switch could cut the ...
National Institute for Health and Care Excellence

Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy

Evidence-based recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-low metastatic or unresectable breast cancer after chemotherapy in adults. This guidance updates and replaces NICE ...
National Institute for Health and Care Excellence

Quality statement 2: Diagnosis of axial spondyloarthritis using imaging

Adults with suspected axial spondyloarthritis and an X‑ray that does not show sacroiliitis have an MRI using an inflammatory back pain protocol. No single test can diagnose axial spondyloarthritis.
National Institute for Health and Care Excellence

Maternal and child nutrition: nutrition and weight management in pregnancy, and nutrition in children up to 5 years

This guideline covers nutrition and weight management in pregnancy for anyone who may become pregnant, is planning to become pregnant or is already pregnant, and nutrition in children up to 5 years.
National Institute for Health and Care Excellence

Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies

There is a simple discount patient access scheme for marstacimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Quality statement 4: Duration of antibiotic treatment for urinary tract infection

When a decision is made to prescribe antibiotics, the shortest course that is likely to be effective should be prescribed to reduce the risk of antimicrobial resistance and adverse effects. Short ...
National Institute for Health and Care Excellence

Guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood: early value assessment

We have moved Health technology evaluation 3 to become HealthTech guidance 660. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, ...
National Institute for Health and Care Excellence

Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer

This guidance has been updated and replaced by NICE technology appraisal guidance on pembrolizumab with pemetrexed and platinum chemotherapy for untreated ...
National Institute for Health and Care Excellence

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...
National Institute for Health and Care Excellence

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal guidance TA673 Published: 17 ...